|
| General Information |
| Business: |
We are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on HIF biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of RBCs in the body and a potentially novel mechanism of treating anemia. Our lead product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to CKD not requiring dialysis. We are conducting a Phase 2b trial for AKB-6548 in patients with anemia secondary to CKD who are not dependent on dialysis and expect data to be available in the fourth quarter of 2014. We have also initiated a development program for patients dependent on dialysis. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
28 |
Founded: |
2007 |
|
| Contact Information |
| Address: |
245 First Street, Suite 1100, Cambridge, MA 02142, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -13.2 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
AKBA |
| Shares (millions): |
5.9 |
| Price Range: |
$17.00 - $17.00 |
| Est.$ Volume |
$ 100.0 mil |
| Manager / Joint Managers |
Morgan Stanley/ Credit Suisse/ UBS Investment Bank |
| Co Managers |
Nomura |
| Expected to Trade |
3/20/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
